By Nanobiotix
A new standard in radiation oncology Through our lead product NBTXR3, we aim to help millions of patients fighting cancer worldwide by improving treatment outcomes without increasing harmful side effects. We believe that radiotherapy-activated NBTXR3 has the potential to become the global standard of care in the treatment of solid tumors. Radiotherapy-activated NBTXR3 is currently being evaluated alone and in combination with other anticancer therapies in ongoing clinical trials that span an array of solid tumors. These trials evaluate the efficacy and safety of NBTXR3 in various cancer types and will provide important insights into the potential applications of it in clinical practice.
